gold-standard drug approval framework, the company said in a statement
Addressing semaglutide-related factors : Ensure adequate hydration to prevent dehydration-related complications Optimize glycemic control, as improved diabetes management may reduce neuropathic contributions Consider physical therapy or exercise programs tailored to patients experiencing rapid weight loss Monitor for proper nutrition including adequate protein, calcium, and vitamin D intake Routine imaging is not recommended for nonspecific low back pain without red flags
Health officials and clinicians increasingly consider GLP-1 drugs to be a major advancement in treating obesity, a condition that disproportionately affects older adults and contributes to a range of costly and debilitating illnesses
Compelling evidence from landmark clinical trials, particularly STEP-HFpEF, STEP-HFpEF DM and SUMMIT, has established the efficacy of GLP-1RAs in improving HF-related symptoms and quality of life, as well as reducing worsening HF events, in the prevalent phenotype of HFpEF in the setting of obesity and T2D
AOM trial: Patients with obesity but without T2D, comparing newer GLP-1 RAs to older GLP-1 RAs and other anti-obesity medications (AOMs)